Prostate cancer test affected by demographic and lifestyle factors

December 12, 2005

The reliability of a prostate cancer-screening test may be compromised by lifestyle and demographic factors, according to a new study. Published in the January 15, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals the (rate of) change in concentration of prostate specific antigen (PSA) over time--a calculation called PSA velocity--can be significantly affected by age, race, and diet, leading to falsely lower or elevated values and possible misinterpretation by doctors. Single determinations of PSA concentration, the most common use of the PSA screening test, were minimally but significantly affected by age and body mass index (BMI).

Studies have shown a decrease in prostate cancer mortality since 1992 and some researchers attribute a portion of that fall to the widespread adoption of the PSA test. But some experts say that PSA concentration alone causes too many false positives and leads to many unnecessary tests, such as biopsies and transrectal ultrasounds. Investigators continue to refine the test, including developing calculations such as PSA velocity, PSA density, and age-specific PSA, or other tests such as percent free PSA. However, there is poor understanding of the effect of other factors, such as diet, race, and weight on PSA and its related measurements.

Alan R. Kristal, Dr.P.H. of the Fred Hutchinson Cancer Research Center in Seattle and colleagues reviewed PSA and PSA velocity data from 3,341 cancer-free men to determine relationships between PSA tests and demographic and lifestyle factors.

PSA velocity was significantly affected by age, race and diet, potentially affecting its clinical interpretation. PSA velocity decreased as men aged, and increased with higher total energy (calorie) diets. PSA velocity in African Americans was on average almost twice the level of Caucasians, and was lower among users of high-dose calcium supplements. Large weight fluctuations also affected PSA velocity. Men who gained weight had lower PSA velocity and those who lost weight had higher PSA velocity.

As was found in other studies, single determinations of PSA concentration increase with age and decrease with obesity. These differences, while statistically significant, were considered minimal and would have little influence on clinical interpretation of PSA value.

While the authors considered the impact of demographic and lifestyle factors on the clinical interpretation of a single PSA concentration was negligible, the clinical impact on interpreting PSA velocity was considered significant. "Race, smoking, age, energy intake, calcium supplement use and weight change were associated with substantial differences in PSA velocity," they conclude, "and clinical interpretation of PSA velocity could be biased by these factors."
-end-
Article: "Associations of Demographic and Lifestyle Characteristics with Prostate-Specific Antigen (PSA) Concentration and Rate of PSA Increase," Alan R. Kristal, Chen Chi, Catherine M. Tangen, Phyllis J. Goodman, Ruth Etzioni, Ian M. Thompson, CANCER; Published Online: December 12, 2005 (DOI: 10.1002/cncr.21603); Print Issue Date: January 15, 2006.

Wiley

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.